Article
"De novo replication repair deficient glioblastoma, IDH-wildtype" is a distinct glioblastoma subtype in adults that may benefit from immune checkpoint blockade.
Acta neuropathologica - 11 Dec 2023
Hadad Sara, Gupta Rohit, Oberheim Bush Nancy Ann, Taylor Jennie W, Villanueva-Meyer Javier E, Young Jacob S, Wu Jasper, Ravindranathan Ajay, Zhang Yalan, Warrier Gayathri, McCoy Lucie, Shai Anny, Pekmezci Melike, Perry Arie, Bollen Andrew W, Phillips Joanna J, Braunstein Steve E, Raleigh David R, Theodosopoulos Philip, Aghi Manish K, Chang Edward F, Hervey-Jumper Shawn L, Costello Joseph F, de Groot John, Butowski Nicholas A, Clarke Jennifer L, Chang Susan M, Berger Mitchel S, Molinaro Annette M, Solomon David A
Abstract excerpt
Glioblastoma is a clinically and molecularly heterogeneous disease, and new predictive biomarkers are needed to identify those patients most likely to respond to specific treatments. Through prospective genomic profiling of 459 consecutive primary treatment-naïve IDH-wildtype glioblastomas in adults, we identified a unique subgroup (2%, 9/459) defined by somatic hypermutation and DNA replication repair deficiency...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.